Asit Biotech | CORPORATE, FV EUR5.7| Pioneering allergy vaccines
ASIT Biotech is a Belgium-based biotechnology company positioned in the growing USD12bn respiratory allergy market with two lead products originating from its ASIT+ platform that are due to report phase I/IIa and phase III results in late 2019/early 2020e. Building on its expertise in the allergy space, ASIT Biotech is leveraging its platform to address the significant unmet medical need in the food allergy market with one product candidate to enter clinical trials in early 2019e.Asit Biotech SA. Asit Biotech SA, formerly Biotech Tools SA, is a Belgium- based company that develops products aimed to prevent negative response of the immune system.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.